The Biomedical Advanced Research and Development Authority (BARDA) awarded the base-five year (60 months) contracts. BARDA is a component of the US Department of Health and Human Services dedicated to developing medical countermeasures (MCMs).
As part of the agreement with the department, SRI will conduct safety testing and pharmacologic analysis of multiple medical countermeasures currently in BARDA’s portfolio.
According to the company, the aim is to advance the potential agents from early stage discovery into the clinic under an FDA-approved Investigational New Drug (IND) application. SRI will also support a subsequent New Drug Application (NDA) or Biologic License Application (BLA).
The second contract involves GLP facilities “to develop, validate and apply analytical methods for evaluating biological distribution and determining appropriate dose levels for achieving drug efficacy.”
SRI International could not be reached for comment.